- About Us
- Advertise
- Contact Us
- CureToday.com
- CancerNetwork.com
- OncLive.com
- Do Not Sell My Information
- Privacy
- Terms & Conditions
© 2021 MJH Life Sciences™ , Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
Lymphomas | Clinical
FDA Approves Crizotinib in Pediatric ALK+ Relapsed or Refractory Systemic ALCL
January 14, 2021
The FDA granted approval to the antineoplastic tyrosine kinase inhibitor, crizotinib, as treatment of pediatric patients 1 year of age and older and young adults with ALK alteration-positive relapsed or refractory systemic anaplastic large cell lymphoma.
Novel JAK1 Inhibitor Safely Induces Preliminary Antitumor Activity in R/R PTCL
January 06, 2021
The investigational selective JAK1 inhibitor, DZD4205, led to anti-tumor activity when given as treatment of patients with relapsed or refractory peripheral T-cell lymphoma , according to results from the phase 1/2 JACKPOT8 clinical trial.
Treating Double-Hit Lymphoma With CAR T-Cell Therapy and Other Drugs
January 04, 2021
During a Targeted Oncology Case-Based Peer Perspectives event, Haifaa Abdulhaq, MD, director, Hematology, and associate clinical professor of Medicine at UCSF Fresno discussed the case of a 63-year-old patient with lymphoma with concurrent MYC and BCL2 rearrangements.
Older Patients With iNHL Experience Similar Benefit to Younger Population in MAGNIFY Study
January 04, 2021
David J. Andorsky, MD, discusses the findings from a subgroup analysis of patients with relapsed/refractory indolent non-Hodgkin lymphoma over the age of 70 in the phase 3b MAGNIFY clinical trial.
Reviewing Treatment Options for Patients With Marginal Zone Lymophoma
December 20, 2020
Tycel J. Phillips, MD, discusses the current treatment options for patients with marginal zone lymphoma.
FDA Approves New Rituximab Biosimilar in NHL, CLL, and Other Hematologic Malignancies
December 18, 2020
The FDA granted approval to rituximab-arrx, a biosimilar to rituximab as treatment of adult patients with non-Hodgkin lymphoma, chronic lymphocytic leukemia, granulomatosis with polyangiitis, and microscopic polyangiitis.
Azacitadine Demonstrates Efficacy in a Phase 2 Trial of PTCL
December 18, 2020
Jia Ruan, MD, PhD, discusses the results of the multicenter phase 2 trial of oral azacitidine plus cyclophosphamide, doxorubicin, vincristine, and prednisone as initial treatment in patients with peripheral T-cell lymphoma.
Early-Phase Study Shows Activity and Safety for TRPH-222 in R/R NHL
December 09, 2020
A phase 1 trial showed early signals of tolerability and efficacy in patients with relapsed or refractory B-cell non-Hodgkin lymphoma with TRPH-222 across dose levels.
Brentuximab Vedotin Tolerable With High Response Rates in Older Patients with cHL
December 08, 2020
In older patients with comorbid classical Hodgkin lymphoma who are deemed unfit for combination chemotherapy, treatment with the antibody dug conjugate brentuximab vedotin appeared tolerable and achieved high response rates that were durable in some patients, according to results from the phase 2 SGN35-015 study.